<DOC>
	<DOCNO>NCT01092026</DOCNO>
	<brief_summary>A pilot study assess feasibility unrelated umbilical cord blood transplantation coinfusion third-party mesenchymal stem cell myeloablative nonmyeloablative conditioning patient hematological malignancy . This multicenter single arm , phase I-II pilot study . The primary objective study determine feasibility UCB HSCT co-infusion third party mesenchymal stem cell assess treatment-related mortality d100 transplant . Patient inclusion criterion : Age 15-60 yr Patients allogeneic stem cell transplantation prefer treatment option , follow hematological malignancy : acute myeloid leukemia , acute lymphoblastic leukemia , high risk myelodysplastic syndrome , advance lymphoproliferative disorder , chronic myeloid leukemia ( refractory intolerant second-line tyrosine kinase inhibitor ) , multiple myeloma Informed consent give Patient exclusion criterion Previous allogeneic transplant Progressive malignant disease Significant organ damage contraindication allotransplantation Significant psychiatric neurological disorder Uncontrolled viral , fungal bacterial infection Pregnancy HIV positive Patients receive either myeloablative reduce intensity conditioning . One 2 cord blood transplant transplant , follow infusion third-party mesenchymal stem cell transplant Adverse event report BHS transplant committee establish protocol review committee organize central monitoring study . Within context allogeneic HSCTx many severe event likely occur . Statistics stop rule The trial stop time reasonable evidence true rate day +100 nonrelapse mortality exceed 0.40 . It intention include initial 20 patient .</brief_summary>
	<brief_title>Unrelated Umbilical Cord Blood Transplantation With Coinfusion Mesenchymal Stem Cells</brief_title>
	<detailed_description>PROTOCOL SYNOPSIS Title study A pilot study assess feasibility unrelated umbilical cord blood transplantation coinfusion third-party mesenchymal stem cell myeloablative nonmyeloablative conditioning patient hematological malignancy . Design study This multicenter single arm , phase I-II pilot study . Primary objective The primary objective study determine feasibility UCB HSCT co-infusion third party mesenchymal stem cell assess treatment-related mortality d100 transplant . Secondary objective - Chimerism multiple time point - Hematopoietic recovery ( neutrophil platelet engraftment ) - Immune recovery - Incidence acute chronic graft-versus-host disease ( GVHD ) - Infectious complication - Disease free survival - Relapse incidence - Overall survival Graft criterion - No peripheral blood marrow donor available 9/10 compatibility level use high resolution type technique - Adequate cord blood transplant available : ) Single cord blood - Minimal 4/6 match ( DR1-high , A-low , B-low ) - Minimal 2 ( 6/6 ) , 2.5 ( 5/6 ) 3 ( 4/6 ) x 10exp7 nucleated cell per kg graft b ) Double cord blood - At least 4/6 common antigen share recipient 2 cord blood transplant - Minimal 3x 10exp7 nucleated cell per kg combine graft Patient inclusion criterion - Age 15-60 yr - Allogeneic stem cell transplantation prefer treatment option : ) High risk acute myeloid leukemia ( AML ) first complete remission ( CR ) - Preceding myelodysplastic syndrome - High risk karyotype ( e.g . monosomy 5 7 , complex ) - FLT3 alteration - &gt; 2 cycle obtain CR - Erythroblastic megakaryocytic leukemia b ) High risk acute lymphoblastic leukemia ( ALL ) first CR - High risk karyotype ( e.g . [ 9 ; 22 ] , [ 4 ; 11 ] , [ 1 ; 19 ] , complex ) - MLL rearrangement c ) Acute leukemia second third remission ) High risk myelodysplastic syndrome : IPSS Intermediate-2 high risk e ) Advanced lymphoproliferative disorder - Diffuse large B-cel non-Hodgkin lymphoma ( NHL ) mantle cell NHL B-prolymphocytic leukemia - Sensitive relapse autologous HSCTx - T-prolymphocytic leukemia - Chronic lymphocytic leukemia - Refractory fludarabine - Adverse karyotype ( del p17 ) f ) Chronic myeloid leukemia - Refractory intolerant second-line tyrosine kinase inhibitor g ) Multiple myeloma - Advanced disease ( select case ) - Informed consent give Patient exclusion criterion - Previous allogeneic transplant - Progressive malignant disease - Significant organ damage contraindication allotransplantation - Creatinine clearance &lt; 60 ml/min - AST/ALT &gt; 3x normal value and/or serum bilirubin &gt; 3 mg/dL - Cardiac failure ( LVEF &lt; 50 % ) - Clinical relevant pulmonary disease : DLCO &lt; 50 % normal - Significant psychiatric neurological disorder - Uncontrolled viral , fungal bacterial infection - Pregnancy - HIV positive Study procedure Patients receive either myeloablative reduce intensity conditioning . One 2 cord blood transplant transplant , follow infusion third-party mesenchymal stem cell transplant Adverse event report BHS transplant committee establish protocol review committee organize central monitoring study . Within context allogeneic HSCTx many severe event likely occur . Statistics stop rule The trial stop time reasonable evidence true rate day +100 nonrelapse mortality exceed 0.40 . It intention include initial 20 patient .</detailed_description>
	<criteria>Allogeneic stem cell transplantation prefer treatment option : High risk acute myeloid leukemia ( AML ) first complete remission ( CR ) Preceding myelodysplastic syndrome High risk karyotype ( e.g . monosomy 5 7 , complex ) FLT3 alteration &gt; 2 cycle obtain CR Erythroblastic megakaryocytic leukemia High risk acute lymphoblastic leukemia ( ALL ) first CR High risk karyotype ( e.g . [ 9 ; 22 ] , [ 4 ; 11 ] , [ 1 ; 19 ] , complex ) MLL rearrangement Acute leukemia second third remission High risk myelodysplastic syndrome : IPSS Intermediate2 high risk Advanced lymphoproliferative disorder Diffuse large Bcel nonHodgkin lymphoma ( NHL ) mantle cell NHL Bprolymphocytic leukemia Sensitive relapse autologous HSCTx Tprolymphocytic leukemia Chronic lymphocytic leukemia Refractory fludarabine Adverse karyotype ( del p17 ) Chronic myeloid leukemia Refractory intolerant secondline tyrosine kinase inhibitor Multiple myeloma Advanced disease ( select case ) Informed consent give Previous allogeneic transplant Progressive malignant disease Significant organ damage contraindication allotransplantation Creatinine clearance &lt; 60 ml/min AST/ALT &gt; 3x normal value and/or serum bilirubin &gt; 3 mg/dL Cardiac failure ( LVEF &lt; 50 % ) Clinical relevant pulmonary disease : DLCO &lt; 50 % normal Significant psychiatric neurological disorder Uncontrolled viral , fungal bacterial infection Pregnancy HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>